BNP Paribas Financial Markets Grows Holdings in Kura Oncology, Inc. (NASDAQ:KURA)

BNP Paribas Financial Markets raised its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 969.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 163,559 shares of the company's stock after purchasing an additional 148,272 shares during the quarter. BNP Paribas Financial Markets owned 0.21% of Kura Oncology worth $1,425,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of KURA. Virtus ETF Advisers LLC lifted its position in Kura Oncology by 71.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock valued at $64,000 after purchasing an additional 3,061 shares during the last quarter. Harbor Advisors LLC bought a new stake in Kura Oncology during the fourth quarter valued at approximately $87,000. E Fund Management Co. Ltd. bought a new stake in Kura Oncology during the fourth quarter valued at approximately $90,000. Optimize Financial Inc bought a new stake in Kura Oncology during the fourth quarter valued at approximately $100,000. Finally, Corient Private Wealth LLC bought a new stake in Kura Oncology during the fourth quarter valued at approximately $109,000.

Kura Oncology Stock Down 9.6%

Shares of KURA stock traded down $0.60 during mid-day trading on Friday, reaching $5.64. 2,677,684 shares of the company's stock traded hands, compared to its average volume of 1,198,563. The company has a market cap of $488.28 million, a P/E ratio of -2.39 and a beta of 0.50. The company's 50-day moving average price is $6.30 and its 200-day moving average price is $8.39. Kura Oncology, Inc. has a 12 month low of $5.41 and a 12 month high of $23.48. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The business had revenue of $14.11 million for the quarter, compared to analyst estimates of $39.08 million. On average, equities analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on KURA shares. Wall Street Zen downgraded shares of Kura Oncology from a "buy" rating to a "hold" rating in a research note on Friday, May 2nd. Wedbush reaffirmed an "outperform" rating and issued a $36.00 target price on shares of Kura Oncology in a research note on Tuesday, April 8th. Cantor Fitzgerald raised shares of Kura Oncology to a "strong-buy" rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 target price on shares of Kura Oncology in a research note on Monday, April 28th. Finally, UBS Group decreased their target price on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, Kura Oncology has an average rating of "Moderate Buy" and an average price target of $24.50.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.